Project Grant R21AG095752
Award Date 9/30/25
Completion Date 8/31/27
Dollars Obligated $388K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
- This Project Grant award of $433,125.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to explore whether extracellular tau protein can modulate neurogenesis through the LRP1 receptor in adult-born granule neurons. The University of Texas Health Science Center at San Antonio is the prime awardee and will conduct this exploratory/developmental research to better understand the role of LRP1 and tau in hippocampal memory function, which is impacted in...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- This $3,360,074 federal Project Grant was awarded on September 15, 2025 by the National Institute on Aging (NIA) under the Aging Research grant program (CFDA 93.866). The grant is funding research led by the University of Pennsylvania to develop short RNA therapeutics that can combat TDP-43 proteinopathy, a key pathological feature of several devastating neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia. The research aims to...
- The National Institute on Aging (NIA), through its Aging Research federal grant program (CFDA 93.866), awarded a $307,312 Project Grant to the University of Iowa to investigate the reversal of tau protein pathology in serotonergic neurons as a potential therapeutic intervention for early-stage Alzheimer's disease and related dementias (ADRD). This 7-month project aims to determine if restoring the function of the PP2A phosphatase enzyme can reduce abnormal tau phosphorylation and mitigate the...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- The University of South Florida (USF) was awarded a $3,297,926 project grant from the National Institute on Aging (CFDA 93.866 - Aging Research) to develop novel biomaterials that can prevent, halt, and potentially cure Alzheimer's disease (AD). The objective of this 4-year project is to advance USF's preliminary work on designing peptide hybrid biomaterials that can stabilize the helical conformation of the amyloid-beta (Aβ) peptide, thereby shifting the equilibrium of Aβ aggregation away...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $3,336,256.00 to the University of Illinois to develop small molecule ligands that target pathological tau signaling in Alzheimer's disease and related dementias. The research aims to identify candidate molecules that can block the toxic effects of misfolded tau protein, which is a key driver of neurodegeneration in these diseases. The grant will fund the screening and initial optimization of...
- The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $638,682 project grant under the Aging Research Federal Grant Program (CFDA 93.866) to the University of Arizona on August 1, 2025. The project, titled "TDP-43 LLPS and Mitochondrial Dysfunction in Neurodegeneration", aims to investigate the relationship between the liquid-liquid phase separation (LLPS) of the TDP-43 protein and mitochondrial dysfunction in neurodegenerative...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $757,027 to the University of Washington to conduct research on the synergistic relationship between tau and TDP-43 proteins in Alzheimer's disease. The research aims to identify mechanisms that drive the interaction between these two pathological hallmarks of Alzheimer's and how they contribute to cognitive decline and neurodegeneration. Key activities include using C. elegans models to...